Notes
Laia Aguirre et al. IPVS 2024
The present study aimed to compare the development of neutralizing antibodies (NA) after vaccinating piglets with MDA either at 3 days or 3 weeks of age with two different MLV PRRSV-1 vaccines.
Notes
Cathy Ardies et al. IPVS 2024
This case-report describes the changes on pressure of infection and mortality after the implementation of an intradermal piglet vaccination program against Porcine Reproductive and Respiratory Syndrome (PRRSV), Porcine Circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mh) on a commercial pig farm.
Notes
Vasco Azeitona Martinset al. IPVS 2024
The aim of this report is to assess the effect of piglet vaccination over nursery mortality on a farm with an intermittent vaccination schedule.
Notes
T Shimada et al. IPVS 2024
The aim of this study was to compare the efficacy of a PRRSV1 vaccine and a PRRSV2 vaccine on a PRRSV2-infected farm in Japan.
Notes
Joel Miranda et al. IPVS 2024
The goal of this study was to evaluate the efficacy of two commercial PRRS MLV vaccines – one based on PRRSV1 (UNISTRAIN® PRRS, HIPRA; IM and ID), and another on PRRSV2 (strain VR-2332; IM) – in growing pigs on a Japanese PRRSV2-positive farm.
Notes
S Sanchéz et al. IPVS 2024
In this study, the efficacy of piglet vaccination was assessed in a multi-origin nursery unit in the southeast of Spain.
Notes
A García Flores et al. IPVS 2024
In the present study we assessed the productive and economic impact of two outbreaks caused by a PRRS strain of increased virulence on a swine farm in Spain.
Notes
Ivan Díaz et al. J Vet Sci. 2023 Sep;24(5):e54.
The aim of the present study was to evaluate the efficacy of a commercial vaccine based on a modified-live PRRSV1 (PRRSV1-MLV) against a Japanese PRRSV2 strain and to compare it to the protection conferred by a commercial PRRSV2-MLV.
Notes
Kyohyun An et al. APVS 2023
The objectives of this trial were to evaluate if a PRRSV1 vaccine could better control coinfection (PRRSV1 and PRRV2) and the time required to detect NA after vaccination in a site 2 farm in Korea.
Notes
Kyohyun An et al. APVS 2023
The purpose of this trial was to check if the stability of a site 2 in Korea coinfected with PRRSV1 and PRRSV2 was improved by switching from a PRRSV2 vaccine to a PRRSV1 vaccine.
Notes
Adthakorn Madapong et al. Veterinary Microbiology 244 (2020).
The objectives of the present study were to investigate the immune response of pigs vaccinated IM or ID with PRRSV-1 MLV (UNISTRAIN® PRRS). The protective efficacy was evaluated against the challenge with HP-PRRSV-2 (sublineage 8.7/HP-PRRSV-2), either alone or in combination with PRRSV-1 (clade A, subtype 1).
Notes
Laia Aguirre et al. North American PRRS Symposium, 2022.
The objective of the present study was to evaluate the immune response of UNISTRAIN® PRRS administered intradermally or intramuscularlly at 3 or 21 days of age in presence of neutralizing maternally derived antibodies.
Notes
Laia Aguirre et al. Porcine Health Manag. 2022 Nov 4
The purpose of this study was to compare the immune response generated by the intramuscular and the intradermal vaccination route against the porcine reproductive and respiratory syndrome virus (PRRSV).
Notes
Laia Aguirre et al. ESPHM 2022
The present study aimed to assess the development of the immune response against PRRSV after vaccination by either the intradermal (ID) or the intramuscular (IM) route in piglets with high MDA levels.
Notes
Lidia de Lucas et al. ESPHM 2022
The objective of this trial was to demonstrate the infection PRRS virus pressure reduction in nurseries owing to a PRRS MLV vaccine applied to piglets in endemically infected farms.
Notes
Almudena Sánchez-Matamoros et al. ESPHM 2021
This study analysed whether the Hipradermic® intradermal needle-free device (ID) improves welfare compared to intramuscular injection with a needle (IM) in piglets.
Notes
Joel Miranda et al. ESPHM 2021
The aim of this study was to estimate the economic impact of PRRS in the nursery phase depending on the PRRS status at the source farm.
Notes
Joel Miranda et al. AASV 2020
The aim of this study was to demonstrate that a PRRSv1 vaccine (UNISTRAIN® PRRS, HIPRA) administered at 2 weeks of age (woa) by ID route can aid in the control of the PRRSv infections in the early nursery phase in European pig farms.
Notes
Daniel Torrents et al. IPVS 2020
The objective of this trial was to analyse how a PRRS positive farm improves its parameters after vaccination of piglets against PRRS.
Notes
Lidia de Lucas et al. IPVS 2020
The purpose of this study was to evaluate the field efficacy of UNISTRAIN® PRRS (MLV PRRSV1, HIPRA, Spain) against PRRSv2 field infection and to determine whether there were differences in terms of piglet performance between UNISTRAIN®PRRS and a commercial MLV PRRSv2 vaccine.
Notes
Torrents, D., Miranda, J., Pedrazuela, R. et al. Porcine Health Management 5, 26, 2019.
Implementation of PRRSV status classification system in swine breeding herds from a large integrated group in Spain.
Notes
Miranda, J. et al.; ESPHM Congress 2019.
This study was conducted to test the efficacy of UNISTRAIN® PRRS when administered intramuscularly or intradermally in pigs against a challenge with a PRRSV2 and a challenge with co-infection with PRRSV2 and PRRSV1.
Notes
Seo, S.W. et al.; IPVS 2018.
In overall, piglet vaccination with UNISTRAIN®PRRS improves productivity especially in farms co-infected with type 1 and 2 PRRSV.
Notes
Miranda, J. et al.; International PRRS Congress 2015.
Vaccination with UNISTRAIN® PRRS significantly reduced the clinical respiratory signs associated with PRRS and the percentage of antibiotic treatments. Moreover, vaccination reduced the percentage of animals with lung lesions and positive to PRRSv.
Notes
Miranda, J. et al.; International PRRS Congress 2015.
Vaccination with UNISTRAIN® PRRS was demonstrated to be a useful tool to reduce mortality, animals with lung lesions positive to PRRSV, number of viraemic animals and the percentage of animals treated with antibiotics on farms with a previous history of PRRS outbreaks.
Notes
Busquet, M. et al.; International PRRS Congress 2015.
The obtained results allow us to conclude that the duration of immunity of the UNISTRAIN® PRRS vaccine was achieved 24 weeks after vaccination. In addition, UNISTRAIN® PRRS administered in piglets by the intradermal route with a suitable device had a comparable effect on the fast clearance of the virus to IM administration using a traditional syringe and needle.
Notes
Busquet, M. et al.; International PRRS Congress 2015.
The obtained results allow us to conclude that vaccination with UNISTRAIN® PRRS is safe when administered in piglets by the intradermal route with a suitable device according to the recommended vaccination program.
Notes
Busquet, M. et al.; International PRRS Congress 2015.
The obtained results allow us to conclude that UNISTRAIN® PRRS administered ID with a suitable device is effective when administered according to the recommended vaccination program and it is a useful tool to reduce viraemia and the negative clinical and productive consequences of PRRSV
Notes
Miranda, J. et al.; International PRRS Congress 2015.
Vaccination with UNISTRAIN® PRRS significantly reduced the viral load in sera, the number of viraemic piglets and the length of the viraemia after a heterologous PRRS challenge with a pathogenic UK strain.
Notes
Miranda, J. et al.; International PRRS Congress 2015.
Vaccination with UNISTRAIN® PRRS significantly reduced the viral load in sera, the number of viraemic piglets and the length of the viraemia after a heterologous PRRS challenge with a pathogenic Spanish strain.
